Immix Biopharma, Inc. (IMMX)
NasdaqCM · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Immix Biopharma, Inc. is trading at $9.25, down 2.22% on the session. The 50 day average sits at $11.71 and the 200 day at $9.24, which puts the stock in a uptrend. RSI is at 33.7, which reads as weak, and MACD is bearish crossover. Volume is below average.
The nearest support is around $8.10 with resistance near $11.72, so that band frames the current range. Average daily movement is roughly $0.77, or about 8.3% of the share price, which is what any stop placement has to allow for. The overall health score of 36 out of 100 combines a trend score of 53, momentum of 20 and a risk score of 30.
Technical indicators
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Company website